Comparison of diglyceride production from choline-containing phosphoglycerides in human neutrophils stimulated with N-formylmethionyl-leucylphenylalanine, ionophore A23187 or phorbol 12-myristate 13-acetate.
The turnover of choline-containing phosphoglycerides (PC) in response to agonist stimulation is well documented in human neutrophils. We have now compared the enzymic pathways of N-formylmethionyl-leucylphenylalanine (fMLP)-, A23187- and phorbol-12-myristate 13-acetate (PMA)-induced diglyceride (DG) and phosphatidic acid (PA) generation in these cells. In order to distinguish between phospholipase C- and D-mediated PC breakdown, human neutrophils were radiolabelled with 1-O-[3H]alkyl-2-acyl-glycero-3-phosphocholine and stimulated in the presence of ethanol or propranolol. The addition of 0.5% ethanol to the incubation mixture resulted in the production of phosphatidylethanol, indicative of phospholipase D activation, in response to all three stimuli. Concomitant with phosphatidylethanol formation was a partial block of PA production. The production of DG was also partially blocked by addition of ethanol. Propranolol (200 microM) was also used to assess the contributions of phospholipases C and D toward DG generation. Inhibition of PA phosphohydrolase by propranolol resulted in the complete abolition of DG generation when neutrophils were stimulated with fMLP. In contrast, propranolol only partially inhibited DG generation in response to A23187 and PMA. These results suggested that DG production in response to fMLP stimulation is mediated via the activation of phospholipase D, whereas A23187- or PMA-induced DG generation may involve more than one pathway. However, examination of the water-soluble choline metabolites produced indicated that phospholipase D was responsible for the production of PA and DG in response to all three stimuli.
Chabot
M C
MC
Department of Biochemistry, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC 27103.
McPhail
L C
LC
Wykle
R L
RL
Kennerly
D A
DA
McCall
C E
CE
D000001:Calcimycin / Q000494:pharmacology*; D002478:Cells, Cultured; D002794:Choline / Q000378:metabolism; D004075:Diglycerides / Q000378:metabolism*; D004347:Drug Interactions; D000431:Ethanol / Q000494:pharmacology; D005994:Glycerophosphates / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D006868:Hydrolysis; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology*; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D010739:Phospholipase D / Q000378:metabolism; D011433:Propranolol / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D010738:Type C Phospholipases / Q000378:metabolism
D004075:Diglycerides; D005994:Glycerophosphates; D000001:Calcimycin; D000431:Ethanol; D009240:N-Formylmethionine Leucyl-Phenylalanine; D011433:Propranolol; D010738:Type C Phospholipases; D010739:Phospholipase D; D002794:Choline; D013755:Tetradecanoylphorbol Acetate